Blog

Dora L. Vallejo – Ardila: Why Australia continues to raise the standards in clinical trial development for precision oncology

Dora L. Vallejo - Ardila/healthcareconsultant.au

Jul 5, 2025, 01:00

Dora L. Vallejo – Ardila: Why Australia continues to raise the standards in clinical trial development for precision oncology

Dora L. Vallejo – Ardila, Senior Medical Monitor/ Clinical Research Physician at Avance Clinical, shared a post on LinkedIn:

“Today, I’m incredibly proud to share one of the key reasons why Australia continues to raise the standards in clinical trial development for precision oncology. Even more importantly, I feel truly fortunate to learn from and be inspired by Dr Frank Lin — the creator, curator, and thought leader behind this visionary initiative.

ARTICANZ: Annotated Registry of Trials in Cancer — Australia and New Zealand.

It is a new informatics initiative designed to transform how clinicians and researchers identify, share, and access cancer clinical trials across our region.

Key features of ARTICANZ

Annotated trial listings
• Includes detailed, context-specific annotations (e.g., cancer type, molecular biomarkers, eligibility nuances).
• Helps clinicians understand which trials are truly relevant to a specific patient profile.

AI-supported search and decision support
• Uses artificial intelligence to rapidly filter and suggest appropriate trials.
• Reduces time-consuming manual searches and improves alignment between molecular tumor board recommendations and trial participation.

Open data and transparency
• Promotes real-time updates on trial status and recruitment.
• Facilitates shared access to up-to-date operational and scientific information.

Integration into clinical workflows
• Designed to support decision-making directly within multidisciplinary and molecular tumor boards.
• Improves efficiency of referrals and patient discussions.

Why is ARTICANZ important?

Today, one of the major barriers to trial participation is information — knowing which trials are open, who is eligible, and what molecular or clinical factors matter most. ARTICANZ aims to democratise this knowledge, reduce inequities in trial access, and accelerate patient entry into potentially life-changing studies.

Who should get involved?
• Medical oncologists
• Clinical trialists and study coordinators
• Academic researchers
• Trial units and cancer centers
• Molecular tumor boards
• Industry partners and sponsors
• Regulators and professional societies

The invitation: We invite you to share and support ARTICANZ within your networks. By contributing your expertise and feedback, you can help build a sustainable, transparent, and collaborative platform that improves outcomes for patients across Australia and New Zealand.”